Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is projected to announce its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $173.5270 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.28). The firm had revenue of $196.87 million during the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 earnings per share. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pacira BioSciences Trading Up 1.0%

Shares of NASDAQ:PCRX opened at $24.88 on Thursday. The company has a market cap of $1.01 billion, a PE ratio of 165.87 and a beta of 0.19. The company’s 50-day moving average price is $22.96 and its 200 day moving average price is $23.06. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $27.64. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54.

Insider Buying and Selling

In other news, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the transaction, the senior vice president directly owned 52,313 shares of the company’s stock, valued at $1,088,633.53. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the transaction, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,320 shares of company stock worth $460,254 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after purchasing an additional 1,165 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Strs Ohio purchased a new position in Pacira BioSciences during the first quarter valued at approximately $75,000. Marshall Wace LLP purchased a new position in Pacira BioSciences during the second quarter valued at approximately $4,550,000. Finally, Sei Investments Co. grew its position in Pacira BioSciences by 35.3% during the second quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock valued at $606,000 after purchasing an additional 6,609 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on PCRX shares. Wall Street Zen downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays dropped their price target on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 26th. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $30.00 price target on shares of Pacira BioSciences in a research report on Friday, January 9th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $30.25.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.